Incyte Corporation (INCY)
Incyte Announces European Commission Approval of Minjuvi® (tafasitamab) for the Treatment of Relapsed or Refractory Follicular Lymphoma
Incyte Announces European Commission Approval of Minjuvi® (tafasitamab) for the Treatment of Relapsed or Refractory Follicular Lymphoma
📈 **POSITIVE** • Medium confidence analysis (70%) • Strong positive business development • Significant competitive advantage **Sentiment:** Positive (95%) **Content type:** Business